161 results
424B5
AGRX
Agile Therapeutics Inc
23 Feb 24
Prospectus supplement for primary offering
4:57pm
to the Warrant Exercise Agreement is expected to occur on or about February 26, 2024, subject to satisfaction of customary closing conditions. The Company
424B5
AGRX
Agile Therapeutics Inc
23 Feb 24
Prospectus supplement for primary offering
4:55pm
to the Warrant Exercise Agreement is expected to occur on or about February 26, 2024, subject to satisfaction of customary closing conditions. The Company
8-K
EX-99.1
o9n0d3d
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-4.3
0uydt 9n9nzwap7izd7
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-10.1
pp3 je1jb79z1
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-4.1
ow7a2dn 6e1
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-4.2
1zij5ow43zpxcjz 146s
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
EX-10.1
8prf088 qk9sr6g
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm